Anticonvulsants

Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021

Retrieved on: 
Friday, May 7, 2021

b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.

Key Points: 
  • b'Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose forms intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.

Nextleaf Solutions Provides Update on CBD Business

Retrieved on: 
Thursday, May 6, 2021

The bulk distilled CBD oils will be supplied to both the wholesale market and directly to provincially-authorized distributors and retailers across Canada by Labs.

Key Points: 
  • The bulk distilled CBD oils will be supplied to both the wholesale market and directly to provincially-authorized distributors and retailers across Canada by Labs.
  • "The receipt of our sales licence has unlocked new revenue segments and this agreement will offer Nextleaf the opportunity to prove the disruptive nature of our technology.
  • Through its wholly-owned subsidiary Nextleaf Labs Ltd, a licensed processor, the Company is a low-cost producer of cannabis distillate and private label THC & CBD oils.
  • Nextleaf is developing delivery technology through its Health Canada Research Licence with sensory evaluation of cannabis via human testing.

Hemp CBD Oil: Technological Advancements Offer Consumers More Choice Through the Continued Refinement and Extraction of THC Variants

Retrieved on: 
Tuesday, May 4, 2021

b'Las Vegas, May 04, 2021 (GLOBE NEWSWIRE) -- There\xe2\x80\x99s no denying that the CBD industry is booming.

Key Points: 
  • b'Las Vegas, May 04, 2021 (GLOBE NEWSWIRE) -- There\xe2\x80\x99s no denying that the CBD industry is booming.
  • This means consumers would either avoid them completely and buy CBD products, or experience them completely and buy THC products.\nNow, with great advancements in THC extraction, variations of hemp CBD oil , gummies, tinctures and more are being created that give consumers a choice of how much \xe2\x80\x98euphoria\xe2\x80\x99 they wish to experience:\nThe hemp industry is experiencing a real shift with the advancement of THC extraction.
  • CBD oil, gummies, distillate and more are now being rivalled by these alternatives that many consumers find more appealing.\nFresh Bros\xe2\x84\xa2 is much more than a licensed CBD and Hemp product manufacturer.
  • They focus on developing transparent, innovative, and reliable products and for high performance individuals, entrepreneurs, and consumers.

Remedy+ Does More Than Merely Take the Edge Off

Retrieved on: 
Tuesday, May 4, 2021

b'FORT LAUDERDALE, Fla., May 4, 2021 /PRNewswire/ --Remedy+ is striving to revolutionize the concept of CBD products.

Key Points: 
  • b'FORT LAUDERDALE, Fla., May 4, 2021 /PRNewswire/ --Remedy+ is striving to revolutionize the concept of CBD products.
  • They are marketed to audiences that are managing chronic pain, coping with stress, and otherwise looking for a way to take the edge off of life\'s challenges.
  • And while that may be one use for cannabidiol products, the folks at Remedy+ pose the question "why stop there?
  • In the words of the brand, its premium CBD products are "designed to help you perform better at work or play."

cbdMD, Inc. to Host Conference Call to Discuss March 31, 2021, Second Quarter Results

Retrieved on: 
Monday, May 3, 2021

b'cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products.

Key Points: 
  • b'cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products.
  • Our cbdMD brand currently includes over 130 SKU\xe2\x80\x99s of high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD bath salts, CBD sleep aids and CBD drink mixes.
  • Please visit www.cbdMD.com , follow cbdMD on Instagram and Facebook , or visit one of the 6,000 retail outlets that carry cbdMD products.
  • cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.

Dosecann Launches Industry-Leading, High-Potency Topical: Dosecann Daily Relief CBD Cream

Retrieved on: 
Monday, May 3, 2021

With 1,200mg of cannabidiol (CBD) per 60 ml unit, Dosecann Daily Relief CBD Cream has double the potency of any CBD topical currently available in the Canadian marketplace and is competitively priced to deliver the best value for a CBD topicali.

Key Points: 
  • With 1,200mg of cannabidiol (CBD) per 60 ml unit, Dosecann Daily Relief CBD Cream has double the potency of any CBD topical currently available in the Canadian marketplace and is competitively priced to deliver the best value for a CBD topicali.
  • \xe2\x80\x9cConsumers use topicals to provide daily relief from a wide variety of symptoms such as localized pain relief, muscle soreness, tension and inflammation.
  • Our team was driven to ensure that Dosecann Daily Relief CBD Cream offers industry-leading potency along with a formulation designed to boost CBD penetration and provide the skin moisturizing properties of high-end skin creams.\xe2\x80\x9d\n\xe2\x80\x9cWe\xe2\x80\x99re excited to launch Dosecann Daily Relief CBD Cream and expand our expertise in the 2.0 segment into topicals,\xe2\x80\x9d said Brad Canario, Brand Director, Auxly.
  • Dosecann Daily Relief CBD Cream\xc2\xa0has a mild, neutral bamboo scent and is packaged in a recyclable glass jar\xc2\xa0with\xc2\xa0a built-in seal to preserve freshness.\nDosecann Daily Relief CBD Cream is the latest cannabis 2.0 release from Auxly, who achieved the #1 market-share position for Cannabis 2.0 products in 2020.

Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences

Retrieved on: 
Wednesday, April 28, 2021

Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.

Key Points: 
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • The company has initiated a Phase 3 trial in refractory status epilepticus.
  • For more information visit www.marinuspharma.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210428006117/en/\n'

Global CBD Nutraceuticals Market Report 2021-2028: Growing Shift Towards Health and Wellness Products has Significantly Increased the Demand

Retrieved on: 
Wednesday, April 28, 2021

The company launched several vegan products including supplements and food-grade products under its new line, MGC Nutraceuticals.

Key Points: 
  • The company launched several vegan products including supplements and food-grade products under its new line, MGC Nutraceuticals.
  • Its new offerings include capsules, water-soluble cannabinoids, and ready-to-drink products containing high-grade phytocannabinoids aimed at reducing stress, boosting immunity, and maintaining muscle and bone structure.
  • This product launch enables the company to tap growing opportunities in the dietary supplement and cannabidiol nutraceuticals market.\nOn the basis of product, the market is segmented into CBD capsules, CBD tinctures, and others.
  • The offline sales channel accounted for a major market share of the global CBD nutraceuticals industry.

Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit

Retrieved on: 
Wednesday, April 28, 2021

b'MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that researchers from the Johns Hopkins University School of Medicine will present the results of new research on the company\xe2\x80\x99s compound Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit.

Key Points: 
  • b'MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, announced today that researchers from the Johns Hopkins University School of Medicine will present the results of new research on the company\xe2\x80\x99s compound Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit.
  • The poster presentation will discuss the preclinical cannabidiol (CBD) derivative that targets endogenous cannabinoid receptor type 2 for the treatment of psychiatric disorders.
  • The data being presented at the conference also demonstrate that Supera-CBD binds to CB2 with almost four-times the affinity of CBD.
  • MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control TNF-\xce\xb1 and other pro-inflammatory cytokines.

Novel Foods CBD Products Validation from the Foods Standards Agency

Retrieved on: 
Tuesday, April 27, 2021

All of these products are manufactured by Rokshaw, EMMAC\xe2\x80\x99s wholly owned subsidiary.\nIn its business guidance on cannabidiol (\xe2\x80\x9cCBD\xe2\x80\x9d) as a novel food, the FSA states that the sale of over the counter CBD products in the UK is allowed only for existing brands that are included in the CBD Public List.

Key Points: 
  • All of these products are manufactured by Rokshaw, EMMAC\xe2\x80\x99s wholly owned subsidiary.\nIn its business guidance on cannabidiol (\xe2\x80\x9cCBD\xe2\x80\x9d) as a novel food, the FSA states that the sale of over the counter CBD products in the UK is allowed only for existing brands that are included in the CBD Public List.
  • To be added to this list, brands selling products containing CBD are required to be linked to a validated dossier.
  • Brands selling products containing CBD without a validated application will be removed from all shelves in the UK.\nCommenting on receiving its CBD brands validation, EMMAC CEO Antonio Costanzo, said: \xe2\x80\x9cWe are delighted that Rokshaw is one of the first companies to have its CBD branded products approved by the FSA.
  • The FSA\xe2\x80\x99s validation is an important milestone because it is another proof point that gives our customers peace of mind that they are purchasing safe and high-quality products.